Meeting NewsVideo

VIDEO: Stereotactic radiotherapy preferred for brain metastases from renal cell carcinoma

MIAMI — Patients with brain metastases from renal cell carcinoma should undergo local treatment when possible, according to a presenter at International Kidney Cancer Symposium.

Stereotactic radiotherapy is the preferred option, Bernard Escudier, MD, told HemOnc Today.

Escudier, former chair of the genitourinary group at Institut Gustave Roussy in Villejuif, France, summarized the incidence and prognostic implications of brain metastases from renal cell carcinoma. He highlighted the potential benefits of radiotherapy, and he also reviewed data on other medical treatment approaches, such as sunitinib (Sutent, Pfizer), nivolumab (Opdivo, Bristol-Myers Squibb) and cabozantinib (Cabometyx, Exelixis).

“My recommendation based on these experiences is to treat locally before trying immunotherapy,” Escudier told HemOnc Today. “There is also rationale to test cabozantinib because of c-Met expression in the brain metastases that we have seen.” by Kristie L. Kahl

Reference:

Escudier B. How should we treat brain metastases from RCC? Presented at: International Kidney Cancer Symposium; Nov. 3-4, 2017; Miami.

Disclosure: Escudier reports honorarium from Bayer, Bristol-Myers Squibb, Calithera, Eisai, Exelixis, Ipsen, Novartis, Pfizer and Roche; and travel grants/support and research grants from Bristol-Myers Squibb, Novartis and Pfizer.

MIAMI — Patients with brain metastases from renal cell carcinoma should undergo local treatment when possible, according to a presenter at International Kidney Cancer Symposium.

Stereotactic radiotherapy is the preferred option, Bernard Escudier, MD, told HemOnc Today.

Escudier, former chair of the genitourinary group at Institut Gustave Roussy in Villejuif, France, summarized the incidence and prognostic implications of brain metastases from renal cell carcinoma. He highlighted the potential benefits of radiotherapy, and he also reviewed data on other medical treatment approaches, such as sunitinib (Sutent, Pfizer), nivolumab (Opdivo, Bristol-Myers Squibb) and cabozantinib (Cabometyx, Exelixis).

“My recommendation based on these experiences is to treat locally before trying immunotherapy,” Escudier told HemOnc Today. “There is also rationale to test cabozantinib because of c-Met expression in the brain metastases that we have seen.” by Kristie L. Kahl

Reference:

Escudier B. How should we treat brain metastases from RCC? Presented at: International Kidney Cancer Symposium; Nov. 3-4, 2017; Miami.

Disclosure: Escudier reports honorarium from Bayer, Bristol-Myers Squibb, Calithera, Eisai, Exelixis, Ipsen, Novartis, Pfizer and Roche; and travel grants/support and research grants from Bristol-Myers Squibb, Novartis and Pfizer.

    See more from International Kidney Cancer Symposium